% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • fezziwig2008 fezziwig2008 Nov 17, 2013 4:01 PM Flag

    UK Royal Pharmacy Society Report on Herceptin SC November 12, 2013

    UK Royal Pharmacy Society November 12, 2013

    How trastuzumab became a major part of our breast cancer treatment arsenal
    Tue, 12/11/2013 - 15:39
    By Jenny Bryan

    SC trastuzumab saves pharmacy time
    In September, a subcutaneous formulation of trastuzumab was approved in Europe as a ready-to-use liquid formulation that is administered as a 600mg/5ml fixed dose every three weeks. Pharmacists at Europe’s largest cancer centre, the Christie NHS Foundation Trust, have calculated that transferring their patients from intravenous to subcutaneous trastuzumab could save 300 hours of pharmacy time and 900 hours of nursing time per year, as well as 900 hours spent by patients attending clinics (PJ 2013;291;452). The trust has estimated that, by eliminating all wastage of trastuzumab, it can make drug cost savings of £200,000 to £300,000 a year, drug preparation savings of £200,000 to £300,000, and savings from homecare of around £100,000.
    (NB Desperately misguided Short -guess the British heard about the Launch.....)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As I keep saying (and you keep ignoring) why the low key EU launches of both SQ Herceptin and HyQ. No adverts, no medical journals, no publicity, nothing. It may technically be launched but I note that Greg mentioned a big zero about sales to date in the CC other than in line with expectations, which means nothing. Now if you were Roche would you prefer to make profits of $100 or $95 because that's the reality of it isn't it? For every SQ treatment that they sell instead of their IV version they make 5% less. That's a tough one for you eh Fezz!

9.52+0.23(+2.48%)Jul 26 4:00 PMEDT